Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of AMG 510 versus docetaxel in previously treated KRAS p.G12C-mutated NSCLC
2019-003582-18Phase 3Unknown
- Sponsor
- Amgen
- Start
- Feb 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of sotorasib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Amgen. Primary endpoint: Progression-free survival. Status: unknown.
02
Drugs
sotorasib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2019-003582-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003582-18.